Yposkesi
YposkesiはフルサービスCDMOである。
- フランス
- Genenthonのスピンオフ, 2016
- 患者団体 AFM-Telethon (イタリア)
- SPI投資ファンド
- 50,000 ft2 (5,000m2)
- up to 100,000 ft2 2021
- Start at 2022 for commercial production and EMA and FDA compliance
- 4 suites for drug substance
- 2 suites for fill & finish
- 175人
- プロセス開発
- 2 to 10L bioreactor (suspension)
- Adherent
- トランスフェクション
- DOE
- Ratio of Plasmid DNA/Transfection reagents/Cell density
- Ration Full/Empty
- vector constructionの比較
- 分析法開発 (analytical development)
- assays qualification
- validation
- ウィルベクターGMP製造 (BSL 2)
- 33 batches / year
- 2 x 200L single use bioreactor
- 500L single use bioreactor
- 24 Cell Factory 10
- purification
- Depth→UF/DF→Affinity→IEX→Size exclusion
- Fill & Finish
- Crystal(R) Closed Vial Technology
- AsepticTechnologies(R), 1mL (Cyclo-Olefin Co-polymer)
- glass vials
- 250μL to 4.5 mL
- 100%目視検査 → Labeling
- BSL2 class C area, and grade A containment isolator
- 手動/半自動
- 300 vials/batch
- Crystal(R) Closed Vial Technology
- QC
- capability
- IR detection western blot
- DLS
- subvisible particle counting(light obscurantism or microscopy)
- and general
- GP QC team
- environmental monitoring test
- utility test (water system)
- Controls of all incoming raw material
- in-process control and release assays
- internally lab
- subcontractors
- Runs stability studies
- <-135℃, <-80℃, <-20℃, 2~8℃, 15℃ to 25℃
- Analytical development, tech transfer, validation
- capability
- QA
- Regulatory Support
- 臨床ロットに必要な文書の作成
- Bill of material
- 新しい原材料の登録
- 臨床ロットに必要な文書の作成
編集履歴
2020/03/31 Mr.HARIKIRI